INDV
Indivior Pharmaceuticals, Inc.
35.50$
-1.9%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -4.7% | -17.7% | +5.7% | -4.6% | -9.9% | +4.2% | +5.6% | -2.5% | -15.0% | -0.6% | +3.0% | |
| – | +3.8% | -37.2% | +8.6% | -7.5% | +5.0% | +5.2% | +7.7% | -3.0% | -29.3% | +2.3% | +8.7% | |
| – | -48.2% | -21.6% | +21.9% | -4.7% | +10.8% | +16.6% | +37.1% | -12.7% | -56.2% | -10.3% | +26.9% | |
| – | -43.2% | -19.6% | +15.0% | -16.1% | +0.6% | +16.6% | +36.7% | -12.7% | -56.2% | -10.3% | +26.9% | |
| – | -2.7% | -2.0% | +4.0% | -3.1% | +1.2% | -4.3% | -1.2% | +13.3% | -6.3% | +11.8% | +0.7% | |
| – | -4.9% | +20.6% | +5.0% | +4.1% | +0.0% | -8.4% | -8.6% | +5.4% | -2.5% | -0.7% | -1.3% | |
| – | – | -60.0% | +0.1% | 0.0% | +0.0% | – | – | – | – | +0.0% | – | |
| – | -94.0% | +1,653.8% | -5.3% | -13.0% | -97.3% | +40.0% | +0.0% | -71.4% | +0.0% | +0.0% | +0.0% | |
| – | +4.3% | -26.3% | +14.9% | -1.5% | +2.2% | -0.4% | +3.0% | -5.1% | -19.8% | +3.0% | +7.5% | |
| – | +4.1% | -33.3% | +17.6% | -5.0% | -2.4% | +7.0% | +5.1% | -8.6% | -5.3% | -14.8% | +11.4% | |
| – | +9.1% | +0.0% | +8.3% | +7.7% | +100.0% | +3.6% | +0.0% | -3.4% | +39.3% | -76.9% | 0.0% | |
| – | -45.1% | +2.6% | +15.0% | +8.7% | +26.0% | +190.5% | -72.7% | -18.0% | +17.1% | -27.1% | -14.3% | |
| – | +0.0% | -0.4% | +0.0% | +0.0% | +34.0% | -1.3% | -1.0% | -1.3% | -4.6% | +67.6% | +0.2% | |
| – | – | – | -1,311.1% | – | – | – | – | – | – | – | – | |
| – | -123.9% | – | -10.4% | -4.8% | -142.4% | – | – | – | – | – | – | |
| – | +3.1% | -2.3% | -2.8% | -1.0% | -4.1% | -3.4% | +0.0% | +4.3% | -3.1% | +3.2% | +0.0% |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.